E39 peptide vaccine

DRACPC ID  DRACPC0102

Active Ingredients   E39 peptide vaccine

Description  A cancer vaccine comprised of human leukocyte antigen (HLA) A2 restricted folate binding protein (FBP) epitope E39 (amino acids 191 to 199), with potential immunostimulatory and antineoplastic activity. Upon intradermal injection, FBP E39 peptide vaccine may induce a specific cytotoxic T-lymphocyte (CTL) response against FBP-expressing tumor cell types. FBP is a membrane-bound, tumor-associated antigen highly overexpressed in various tumor cell types, such as in breast, ovarian and endometrial cancers; E 39 is a strong immunogenic peptide.

Synonyms  FBP E39 Peptide Vaccine; Folate Binding Protein E39 Peptide Vaccine; E39 Peptide Vaccine

Type  Biotech

Disease  Breast Cancer, Ovarian Cancer

Classification

  

Peptide and derivative Vaccine 

Structure Information


Molecular Formula  Not available

Molecular Weight  Not available

Active Sequence  EIWTHSYKV

Sequence Length  9

Modification  Not available

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  Not available

InChI  Not available

InChI_Key Not available

SMILES  Not available

External Codes


PubChem CID  Not available

DrugBank Accession Number  Not available

NCI Thesaurus Code  C101530  

UNII  Not available  

CAS  Not available



Drug approval


Drug indication
    Investigated for use/treatment in Breast Cancer, Ovarian Cancer.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT02019524 Phase Ib Trial of Two Folate Binding Protein (FBP) Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Breast Cancer; Ovarian Cancer Phase 1 Treatment
NCT01580696 Phase I/IIa Trial of Folate Binding Protein (FBP) Peptide (E39) Vaccine in Ovarian and Endometrial Cancer Patients Ovarian Cancer; Endometrial Cancer; Fallopian Cancer; Peritoneal Cancer Phase 1/2 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DRACP is developed by Dr.Zheng's team.